|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400082160 |
|
最近更新日期: Date of Last Refreshed on: |
2024-03-22 08:54:06 |
|
注册时间: Date of Registration: |
2024-03-22 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
CPET筛查和术前肺康复训练对肺癌肺叶切除术患者术后早期康复的影响 |
|
Public title: |
Effect of CPET screening and preoperative pulmonary rehabilitation training on early postoperative rehabilitation in patients undergoing lobectomy for lung cancer |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
CPET筛查和术前肺康复训练对肺癌肺叶切除术患者术后早期康复的影响 |
|
Scientific title: |
Effect of CPET screening and preoperative pulmonary rehabilitation training on early postoperative rehabilitation in patients undergoing lobectomy for lung cancer |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
冯婧 |
研究负责人: |
冯婧 |
|
Applicant: |
Jing Feng |
Study leader: |
Jing Feng |
|
申请注册联系人电话: Applicant telephone: |
+86 157 3564 1483 |
研究负责人电话: Study leader's telephone: |
+86 157 3564 1483 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
892080755@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
892080755@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市虹口区三门路1279号 |
研究负责人通讯地址: |
上海市虹口区三门路1279号 |
|
Applicant address: |
No. 1279 Sanmen Road, Hongkou District, Shanghai |
Study leader's address: |
No. 1279 Sanmen Road, Hongkou District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海市第四人民医院 |
||
|
Applicant's institution: |
Shanghai Fourth People's Hospital |
||
|
研究负责人所在单位: |
上海市第四人民医院 |
||
|
Affiliation of the Leader: |
Shanghai Fourth People's Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023040-001 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市第四人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Shanghai Fourth People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-04-25 00:00:00 |
||
|
伦理委员会联系人: |
李浥庭 |
||
|
Contact Name of the ethic committee: |
Yiting Li |
||
|
伦理委员会联系地址: |
上海市虹口区三门路1279号 |
||
|
Contact Address of the ethic committee: |
No. 1279 Sanmen Road, Hongkou District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 5560 3999 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海市第四人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Fourth People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市虹口区三门路1279号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 1279 Sanmen Road, Hongkou District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
虹口区卫生健康委员会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hongkou District Health Committee |
||||||||||||||||||||||
|
Target disease: |
Lung cancer |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
通过在术前进行肺康复干预,观察对择期行肺叶切除术手术的肺癌患者(大于等于65岁)术后早期功能的改善作用。 |
||||||||||||||||||||||
|
Objectives of Study: |
Through preoperative pulmonary rehabilitation intervention, the effect of improving early postoperative function in lung cancer patients (≥65 years old) scheduled for elective lobectomy was observed. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1) 年龄65岁及以上; 2) 肺癌诊断均符合《中华医学会肺癌临床诊疗指南(2018版)》且拟行胸腔镜肺叶切除术的患者; 3) 意识清楚,无认知、语言及运动功能障碍及运动禁忌症的患者; 4) 患者本人及家属同意入组并签署参加本项研究的临床知情同意书者; 5) 美国麻醉协会ASA分级I-III; |
||||||||||||||||||||||
|
Inclusion criteria |
1) Age 65 years and above; 2) Patients whose lung cancer diagnoses are all in accordance with the Chinese Medical Association Lung Cancer Clinical Diagnosis and Treatment Guidelines (2018 Edition) and who are proposed to undergo thoracoscopic lobectomy; 3) Patients who are conscious, without cognitive, speech and motor dysfunction and contraindications to exercise; 4) Patients and their families who agreed to be enrolled and signed the clinical informed consent to participate in this study; 5) American Society of Anaesthesiologists ASA classification I-III; |
||||||||||||||||||||||
|
排除标准: |
1) 全身多处转移患者; 2) 拟行全肺或者两处以上肺叶切除的患者; 3) 接受放疗或化疗等辅助治疗的患者; 4) 合并心、脑、肾等脏器严重器质性病变或功能不全患者; 5) 严重的身体行为能力受限,需卧床休息的患者; 6) 沟通问题,如严重的听力、视力或语言障碍; 7) 有精神障碍患者; 8) 3个月内参加过其他相关临床研究的患者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Patients with multiple metastases throughout the body; 2) Patients with proposed total lung or two or more lobectomies; 3) patients receiving adjuvant treatment such as radiotherapy or chemotherapy; 4) Patients with severe organic lesions or insufficiency of organs such as heart, brain and kidney; 5) Patients with severe physical behavioural limitations requiring bed rest; 6) Patients with communication problems such as severe hearing, vision or speech disorders; 7) Patients with mental disorders; 8) Patients who have participated in other relevant clinical studies within 3 months; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-10-01 00:00:00至 To 2025-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-03-25 00:00:00 至 To 2025-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本试验拟采用单中心随机对照试验设计。将符合纳入标准的受试者随机编号,采用IBM SPSS 23.0软件产生随机分配方案。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This trial was intended to be a single centre randomised controlled trial design. Subjects meeting the inclusion criteria will be randomly numbered and a random allocation scheme will be generated using IBM SPSS 23.0 software. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
采用盲法评价,由不知分组情况的第三人进行疗效评价;资料总结阶段采用盲法统计分析,实行研究者、操作者、统计者三分离。数据登记和分析者对分组不知情。 |
|
Blinding: |
The evaluation of efficacy was carried out by a blinded third person who was unaware of the subgroups, and the data summary phase was carried out by blinded statistical analysis, with the separation of the researcher, the operator and the statistician. The person registering and analysing the data had no knowledge of the subgroups. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
公开后可通过邮件向课题组获取 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After sharing time, everyone can get the data from us by email. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
原始数据将直接采集至excel表中。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Primary data will be put into the excel. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |